Adrenaline
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Adrenaline (Epinephrine): Drug Profile — TxGNN Prediction Pending
One-Sentence Summary
Adrenaline (Epinephrine) is a well-established catecholamine used in emergency medicine, most notably for anaphylaxis, cardiac arrest, and severe bronchospasm. No TxGNN drug repurposing predictions are currently available for this candidate — the prediction pipeline has not yet been completed, and critical data gaps remain unresolved. This report documents the current regulatory status in Malaysia and outlines the steps required before a repurposing evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not populated in current Evidence Pack |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 — Model prediction not yet run; no supporting studies in pack |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 17 |
| Recommended Decision | Hold |
Why Is a Prediction Not Yet Available?
The predicted_indications array in the current Evidence Pack is empty. Two upstream data gaps are blocking the repurposing evaluation:
- DG001 (Blocking) — Package insert warnings and contraindications have not been retrieved from the regulatory authority. Without this, the safety pre-screening step (S1) cannot be completed.
- DG002 (High) — Mechanism of action (MOA) data has not been loaded from DrugBank. This prevents mechanistic plausibility analysis for any predicted indication.
From established pharmacology, Adrenaline acts as a non-selective adrenergic agonist at α₁, α₂, β₁, and β₂ receptors, producing vasoconstriction, bronchodilation, positive chronotropy, and inotropic effects. Its classical indications include anaphylaxis, pulseless cardiac arrest, severe asthma, and croup. Whether TxGNN identifies novel repurposing opportunities outside these established uses remains to be determined once the prediction pipeline is executed with complete input data.
Malaysia Market Information
17 active registrations were identified in the NPRA database for Adrenaline (Epinephrine). However, individual product details were not populated in the current Evidence Pack and require a follow-up data retrieval step.
| Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
Note: 17 records are confirmed in the NPRA registry. Full product details (licence numbers, brand names, dosage forms, approved indication text) must be retrieved from the NPRA database to complete this section.
Safety Considerations
Please refer to the package insert for safety information.
Safety data for Adrenaline is not available in the current Evidence Pack (Data Gap DG001, severity: Blocking). No key warnings, contraindications, or drug–drug interaction data have been populated. This is the highest-priority remediation item before any repurposing evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for Adrenaline is incomplete at a foundational level — no TxGNN predictions have been generated, MOA data is absent, and safety data has not been retrieved. A Hold decision is required until the blocking and high-severity data gaps are resolved.
To proceed, the following is needed:
- [Blocking] Download and parse the NPRA/TFDA package insert PDF to extract warnings, contraindications, and special population data (remediation for DG001)
- [High] Query the DrugBank API to retrieve MOA, pharmacodynamics, and toxicity data for Adrenaline (remediation for DG002)
- Retrieve full licence detail records for the 17 confirmed NPRA registrations (product names, dosage forms, approved indication text)
- Re-run the TxGNN prediction pipeline for Adrenaline once input data is complete, to generate
predicted_indications - Re-generate the Evidence Pack and proceed to full evaluation once all data gaps are resolved
⚠️ This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate identified by TxGNN requires clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.